2019
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry
Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta Haematologica 2019, 143: 40-50. PMID: 31315113, DOI: 10.1159/000500666.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaFront-line therapyComplete responseRelapsed diseaseT-cell lymphomaRefractory patientsInitial treatmentPrimary refractoryOverall survivalPeripheral T-cell lymphoma patientsResponse/stable diseaseT-cell lymphoma patientsAggressive T-cell lymphomaSingle-agent regimensDays of enrollmentObjective response ratePrimary refractory diseaseSecond-line settingSecond-line therapyActive single agentProspective outcome dataSingle-agent therapyLonger overall survivalUnmet medical needGood responseSingle agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry
Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter‐Brown L, Pro B, Shustov AR, Foss FM, Jain S. Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry. American Journal Of Hematology 2019, 94: 641-649. PMID: 30896890, PMCID: PMC7928240, DOI: 10.1002/ajh.25463.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaComprehensive Oncology MeasuresT-cell lymphomaCombination chemotherapyFirst retreatmentSingle agentCombination therapyR diseaseTreatment RegistryEligibility criteriaR Peripheral T Cell LymphomaHematopoietic stem cell transplantationPrior systemic therapyComplete response rateMedian overall survivalProgression-free survivalStem cell transplantationPrimary endpointAdverse eventsOverall survivalSystemic therapyMore patientsRandomized trialsGrade 3
2015
The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project
Bellei M, Nabhan C, Pesce EA, Conte L, Vose JM, Foss F, Federico M. The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project. Current Hematologic Malignancy Reports 2015, 10: 448-455. PMID: 26449717, DOI: 10.1007/s11899-015-0291-0.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell ProjectLymphoma RegistryCell lymphomaManagement of PTCLFuture clinical trialsOptimal therapeutic strategyT-cell lymphomaB-cell lymphomaPoor prognosisLymphoma treatmentLarge registriesClinical trialsLymphoid malignanciesTherapeutic strategiesNew agentsRegistryHeterogeneous groupPrognosisLymphoma
2010
Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women
Han X, Zheng T, Foss F, Holford TR, Shuangge M, Zhao P, Dai M, Kim C, Zhang Y, Bai Y, Zhang Y. Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. Leukemia & Lymphoma 2010, 51: 1047-1054. PMID: 20350273, PMCID: PMC3110752, DOI: 10.3109/10428191003690364.Peer-Reviewed Original ResearchConceptsHazard ratioHigh intakeNon-Hodgkin lymphoma survivalCox proportional hazards modelRisk of deathIntake of vegetablesProportional hazards modelCitrus fruit consumptionIncident NHLOverall survivalNHL patientsGreen leafy vegetablesFruit intakeNHL subtypesFemale casesConnecticut womenNHL survivalLymphoma survivalHazards modelFruit consumptionIntakeSurvivalPatientsNHLUseful strategy
2009
Genetic polymorphisms in the metabolic pathway and non‐Hodgkin lymphoma survival
Han X, Zheng T, Foss FM, Lan Q, Holford TR, Rothman N, Ma S, Zhang Y. Genetic polymorphisms in the metabolic pathway and non‐Hodgkin lymphoma survival. American Journal Of Hematology 2009, 85: 51-56. PMID: 20029944, PMCID: PMC2964927, DOI: 10.1002/ajh.21580.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overArylamine N-AcetyltransferaseConnecticutCytochrome P-450 CYP2E1FemaleFollow-Up StudiesGenotypeGlutathione S-Transferase piGlutathione TransferaseHumansIsoenzymesKaplan-Meier EstimateLeukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularMiddle AgedPolymorphism, Single NucleotideProportional Hazards ModelsRegistriesYoung AdultConceptsNHL survivalHazard ratioLymphoma survivalChronic lymphocytic leukemia/small lymphocytic lymphomaNon-Hodgkin lymphoma survivalCox proportional hazards modelConnecticut Tumor RegistryKaplan-Meier curvesGenetic polymorphismsSmall lymphocytic lymphomaProportional hazards modelGlutathione S-transferaseCytochrome P450NHL prognosisN-acetyltransferasesTumor RegistryTumor characteristicsIncident casesLymphocytic lymphomaMetabolic pathwaysHazards modelSurvival analysisDrug metabolismEnvironmental carcinogensSurvival